En savoir plus
Pramipexole hydrochloride (PPX) and ropinirole hydrochloride (RPN), are nonergot dopamine agonist, selective for dopamine D2 and D3 receptors, in contrast to ergot derivatives that also have activity at D1 type and other nondopaminergic neurotransmitter receptors, indicated for the treatment of the signs and symptoms of Parkinson's disease. The nigrostristrial neurodegeneration that proceeds over the cource of parkinson's disease limits the no. of striatal nerve terminals that are available to decarboxylate levodopa to dopamine. Drugs (PPX and RPN) that act directly to stimulate dopamine receptors, however do not require functioning dopaminergic nerve terminals and can be useful in the management of last- stage disease problems during levodopa therapy. The present work deals with development of validated analytical methods for these antiparkinson's agents in bulk and in their respective pharmaceutical dosage forms by RP-HPLC and HPTLC techniques and different UV spectrophotometric methods.
A propos de l'auteur
Ms. Madhuri Chaudhari - Master of Pharmacy in Quality Assurance Technology. Ms. Smita Bedis - Master of Pharmacy in Pharmaceutical Chemistry. Mr. Aniket Garud - Master of Pharmacy in Pharmacology.
